enGene Therapeutics Inc.
ENGNW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001980845
In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.54M in total; no superinvestor holds it.
Other share classesENGN
13F holders, Q3 2025
Institutional positions in enGene Therapeutics Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- +3 vs. Q2 2025
- Shares held
- 4.58M
- −182.4K (−3.8%) vs. Q2 2025
- Total value
- $3.29M
- −$410.7K (−11.1%) vs. Q2 2025
- New holders
- 3
- 0 more added
- Sold out
- 0
- 3 more reduced
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENGNW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 11 | $1.54M |
| Q1 2026 | 11 | $12.9M |
| Q4 2025 | 14 | $13.9M |
| Q3 2025 | 17 | $3.29M |
| Q2 2025 | 15 | $3.70M |
| Q1 2025 | 14 | $2.91M |
| Q4 2024 | 15 | $4.02M |
| Q3 2024 | 14 | $9.20M |
| Q2 2024 | 16 | $6.54M |
| Q1 2024 | 16 | $28.6M |
| Q4 2023 | 25 | $6.26M |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding enGene Therapeutics Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FCPM III Services B.V. | 2,878,148 | $2.07M | 0.41% | 00.0% | Unchanged |
| BVF Inc | 945,402 | $680.7K | 0.03% | 00.0% | Unchanged |
| Saba Capital Management, L.P. | 178,334 | $127.5K | 0.00% | 00.0% | Unchanged |
| Calamos Advisors LLC | 150,000 | $108.0K | 0.00% | 00.0% | Unchanged |
| D. E. Shaw & Co., Inc. | 104,622 | $75.3K | 0.00% | 00.0% | Unchanged |
| Omega Fund Management, LLC | 89,702 | $63.4K | 0.03% | −231,800−72.1% | Reduced |
| Wolverine Asset Management LLC | 59,431 | $42.2K | 0.00% | +59,431 | New |
| Tenor Capital Management Co., L.P. | 55,243 | $39.2K | 0.00% | 00.0% | Unchanged |
| Blue Owl Capital Holdings LP | 36,100 | $25.6K | 0.01% | 00.0% | Unchanged |
| Whitebox Advisors LLC | 31,000 | $22.0K | 0.00% | 00.0% | Unchanged |
| State of Wisconsin Investment Board | 19,049 | $13.7K | 0.00% | −4,521−19.2% | Reduced |
| CSS LLC | 16,895 | $12.0K | 0.00% | 00.0% | Unchanged |
| Caption Management, LLC | 7,144 | $5.07K | 0.00% | +7,144 | New |
| UBS Group AG | 6,706 | $4.76K | 0.00% | −12,958−65.9% | Reduced |
| Bank of America Corp | 300 | $213 | 0.00% | 00.0% | Unchanged |
| Clear Street Group Inc. | 300 | $213 | 0.00% | +300 | New |
| Toronto Dominion Bank | 101 | $72 | 0.00% | 00.0% | Unchanged |
| Clear Street LLC | – | – | – | – | Not filed |